Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Käräjämäki, Aki Juhani ^a   Kettunen, Olli ^a   Lepojärvi, Samuli ^a   Koivurova, Olli Pekka ^a   Kesäniemi, Y Antero ^a   Huikuri, Heikki ^a   Ukkola, Olavi ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ELDERLY CARE; FEMALE; FINN (CITIZEN); HEART ATRIUM; HEART LEFT ATRIUM DIAMETER; HUMAN; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NONALCOHOLIC FATTY LIVER; PREVALENCE; TRANSIENT ELASTOGRAPHY; COMPLICATION; ELASTOGRAPHY; FINLAND; LIVER; MIDDLE AGED; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; FINLAND; HUMANS; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85015333744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173855     Document Type: Article

References (53)

1. Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014 Mar 14; 20(10):2515-2532. https://doi.org/10.3748/wjg.v20.i10.2515 PMID: 24627588
2. Atta HM. Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol 2015 May 7; 21(17):5138-5148. https://doi.org/10.3748/wjg.v21.i17.5138 PMID: 25954087
3. Iredale JP, Bataller R. Identifying molecular factors that contribute to resolution of liver fibrosis. Gastroenterology 2014 May; 146(5):1160-1164. https://doi.org/10.1053/j.gastro.2014.03.019 PMID: 24680971
4. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish Murad S, Taimr P, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 2016 Jan; 63(1):138-147. https://doi.org/10.1002/hep.27981 PMID: 26171685
5. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012 Feb 18; 379(9816):648-661. https://doi.org/10.1016/S0140-6736(11)61514-6 PMID: 22166900
6. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 Jul 11; 114(2):119-125. https://doi.org/10.1161/CIRCULATIONAHA.105.595140 PMID: 16818816
7. Karajamaki AJ, Patsi OP, Savolainen M, Kesaniemi YA, Huikuri H, Ukkola O. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One 2015 Nov 16; 10(11):e0142937. https://doi.org/10.1371/journal.pone.0142937 PMID: 26571029
8. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8(2):e57183. https://doi.org/10.1371/journal.pone.0057183 PMID: 23451184
9. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008 Apr; 134(4):960-974. https://doi.org/10.1053/j.gastro.2008.01.034 PMID: 18395077
10. Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015 May; 9(5):603-627. https://doi.org/10.1586/17474124.2015.1007955 PMID: 25694178
11. Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesaniemi YA. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 1999 Feb; 245(2):163-174. PMID: 10081519
12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015 Mar; 16(3):233-270. https://doi.org/10.1093/ehjci/jev014 PMID: 25712077
13. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2009 Jul; 158(1):111-117. https://doi.org/10.1016/j.ahj.2009.05.010 PMID: 19540400
14. Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 2012 Jan; 21 Suppl 1:141-147.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009 May 5; 150(9):604-612. PMID: 19414839
16. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013 Oct; 59(4):859-871. https://doi.org/10.1016/j.jhep.2013.05.044 PMID: 23751754
17. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016 Jul; 64(1):73-84. https://doi.org/10.1002/hep.28431 PMID: 26707365
18. Petta S, Di Marco V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011 Jun; 33(12):1350-1360. https://doi.org/10.1111/j.1365-2036.2011.04668.x PMID: 21517924
19. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010 Feb; 51(2):454-462. https://doi.org/10.1002/hep.23312 PMID: 20101745
20. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007 Apr; 45(4):846-854. https://doi.org/10.1002/hep.21496 PMID: 17393509
21. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016 Jun; 59(6):1121-1140. https://doi.org/10.1007/s00125-016-3902-y PMID: 27053230
22. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015 May; 61(5):1547-1554. https://doi.org/10.1002/hep.27368 PMID: 25125077
23. HILL AB. The Environment and Disease: Association Or Causation? Proc R Soc Med 1965 May; 58:295-300. PMID: 14283879
24. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011 Apr; 25(2):195-206. https://doi.org/10.1016/j.bpg.2011.02.005 PMID: 21497738
25. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008 May; 134(6):1655-1669. https://doi.org/10.1053/j.gastro.2008.03.003 PMID: 18471545
26. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015 Apr; 13(4):643-54.e1-9; quiz e39-40. https://doi.org/10.1016/j.cgh.2014.04.014 PMID: 24768810
27. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016 Aug; 65(8):1038-1048. https://doi.org/10.1016/j.metabol.2015.12.012 PMID: 26823198
28. Liang S, Kisseleva T, Brenner DA. The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts. Front Physiol 2016 Feb 2; 7:17. https://doi.org/10.3389/fphys.2016.00017 PMID: 26869935
29. Sanchez-Valle V, Chavez-Tapia NC, Uribe M, Mendez-Sanchez N. Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem 2012; 19(28):4850-4860. PMID: 22709007
30. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012 Dec 4; 60(22):2263-2270. https://doi.org/10.1016/j.jacc.2012.04.063 PMID: 23194937
31. Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc Res 2015 Mar 1; 105(3):238-247. https://doi.org/10.1093/cvr/cvv001 PMID: 25587048
32. Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 2010 Sep; 21(9):1064-1070. https://doi.org/10.1111/j.1540-8167.2010.01774.x PMID: 20455973
33. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 2008 Feb; 94(2):200-204. https://doi.org/10.1136/hrt.2006.108688 PMID: 17575330
34. Joseph P, Ishai A, MacNabb M, Abdelbaky A, Lavender ZR, Ruskin J, et al. Atrial fibrillation is associated with hematopoietic tissue activation and arterial inflammation. Int J Cardiovasc Imaging 2016 Jan; 32(1):113-119. https://doi.org/10.1007/s10554-015-0766-z PMID: 26411879
35. Youn JY, Zhang J, Zhang Y, Chen H, Liu D, Ping P, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol 2013 Sep; 62:72-79. https://doi.org/10.1016/j.yjmcc.2013.04.019 PMID: 23643589
36. Zhang J, Youn JY, Kim AY, Ramirez RJ, Gao L, Ngo D, et al. NOX4-Dependent Hydrogen Peroxide Overproduction in Human Atrial Fibrillation and HL-1 Atrial Cells: Relationship to Hypertension. Front Physiol 2012 Jun 5; 3:140. https://doi.org/10.3389/fphys.2012.00140 PMID: 22679437
37. Li LC, Li J, Gao J. Functions of galectin-3 and its role in fibrotic diseases. J Pharmacol Exp Ther 2014 Nov; 351(2):336-343. https://doi.org/10.1124/jpet.114.218370 PMID: 25194021
38. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA 2006 Mar 28; 103(13):5060-5065. https://doi.org/10.1073/pnas.0511167103 PMID: 16549783
39. Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol 2013 Dec 21; 19(47):8831-8849. https://doi.org/10.3748/wjg.v19.i47.8831 PMID: 24379606
40. Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, Yorgun H, et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol 2015 Mar 1; 115(5):647-651. https://doi.org/10.1016/j.amjcard.2014.12.021 PMID: 25604929
41. Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT, et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J 2014 May; 167(5):729-34.e1. https://doi.org/10.1016/j.ahj.2014.02.009 PMID: 24766984
42. Kornej J, Schmidl J, Ueberham L, John S, Daneschnejad S, Dinov B, et al. Galectin-3 in patients with atrial fibrillation undergoing radiofrequency catheter ablation. PLoS One 2015 Apr 15; 10(4):e0123574. https://doi.org/10.1371/journal.pone.0123574 PMID: 25875595
43. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial fibrillation: Simple bystander, player or both? Clin Biochem 2015 Aug; 48(12):818-822. https://doi.org/10.1016/j.clinbiochem.2015.04.021 PMID: 25952321
44. Spronk HM, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau DH, et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J 2017 Jan 1; 38(1):38-50. https://doi.org/10.1093/eurheartj/ehw119 PMID: 27071821
45. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009 Jan 10; 373(9658):155-166. https://doi.org/10.1016/S0140-6736(09)60040-4 PMID: 19135613
46. Fu R, Wu S, Wu P, Qiu J. A study of blood soluble P-selectin, fibrinogen, and von Willebrand factor levels in idiopathic and lone atrial fibrillation. Europace 2011 Jan; 13(1):31-36. https://doi.org/10.1093/europace/euq346 PMID: 20852292
47. Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011 Sep; 35(8-9):526-533. https://doi.org/10.1016/j.clinre.2011.03.011 PMID: 21570930
48. Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011 Sep; 9(9):1713-1723. https://doi.org/10.1111/j.1538-7836.2011.04429.x PMID: 21729237
49. Gonzalez-Reimers E, Quintero-Platt G, Martin-Gonzalez C, Perez-Hernandez O, Romero-Acevedo L, Santolaria-Fernandez F. Thrombin activation and liver inflammation in advanced hepatitis C virus infection. World J Gastroenterol 2016 May 14; 22(18):4427-4437. https://doi.org/10.3748/wjg.v22.i18.4427 PMID: 27182154
50. Anstee QM, Goldin RD, Wright M, Martinelli A, Cox R, Thursz MR. Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost 2008 Aug; 6(8):1336-1343. https://doi.org/10.1111/j.1538-7836.2008.03015.x PMID: 18485088
51. Rullier A, Gillibert-Duplantier J, Costet P, Cubel G, Haurie V, Petibois C, et al. Protease-activated receptor 1 knockout reduces experimentally induced liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008 Jan; 294(1):G226-35. https://doi.org/10.1152/ajpgi.00444.2007 PMID: 17962354
52. Knight V, Tchongue J, Lourensz D, Tipping P, Sievert W. Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells. Hepatology 2012 Mar; 55(3):879-887. https://doi.org/10.1002/hep.24784 PMID: 22095855
53. Pavlov CS, Casazza G, Nikolova D, Tsochatzis E, Burroughs AK, Ivashkin VT, et al. Transient elasto-graphy for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2015 Jan 22; 1:CD010542. https://doi.org/10.1002/14651858.CD010542.pub2 PMID: 25612182